Blue Ocean Technologies & FlexTrade Systems Announce Connectivity Partnership
22.2.2023 17:04:00 EET | Business Wire | Press release
FlexTrade Systems (@FlexTrade), a global leader in high-performance multi-asset sell-side technology and Blue Ocean Technologies (BOT), a unique capital markets fintech leader in global afterhours trading, announced today a connectivity partnership to broaden access to FlexTrade’s sell-side order management solutions for broker-dealer subscribers. As part of the partnership, FlexTrade is offering broker-dealer clients access to the Blue Ocean ATS trading platform for after–hours trading in US equities from 8:00 pm – 4:00 am EST, further driving development within the 24-hour global equities trading sector.
Brian Hyndman, President and CEO of Blue Ocean Technologies and Blue Ocean ATS, commented, “We are delighted to partner with a respected industry leader such as FlexTrade. Blue Ocean Technologies average daily volume has grown 230% in 2023 from 2022, validating the overall need for the offering providing additional choices for investors that want to manage their risk., validating the overall need for the offering providing additional choices for investors that want to manage their risk. The expansion is due in large part to connectivity partnerships with trading platforms like FlexTrade Systems. With this newest partnership, FlexTrade is providing users with access to our Blue Ocean Sessions service, underscoring the importance of providing users with new routing choices, more trading flexibility, and transparency after hours. We are excited to continue growing our reach for traders globally,” he added.
FlexTrade Systems’ Shane Remolina, Director of Business Development, Sell-Side Trading Solutions added, “FlexTrade’s objectives include providing best-in-class service and support coupled with cutting-edge feature sets and functionality to our clients. Partnering with Blue Ocean is a natural fit and next step that will enable clients with large trading flows in the APAC region to access Blue Ocean’s overnight session in US names. We are extremely excited to have added Blue Ocean connectivity to FlexTrade’s already best-in-class institutional grade retail trading suite.”
About Blue Ocean Technologies:
Blue Ocean Technologies, LLC (BOT) is a unique capital markets fintech company empowering global investors by making trading possible during US overnight trading hours. Blue Ocean Technologies’ US broker dealer subsidiary, Blue Ocean ATS, LLC, and its trading system Blue Ocean Alternative Trading System (BOATS), currently trade US National Market System (NMS) stocks from 8:00 pm to 4:00 am ET from Sunday – Thursday. Founded in 2019, Blue Ocean ATS is on a mission to transform US trading to Global trading via its flagship service, Blue Ocean Session, providing access and transparency to subscribers in all time zones during non-traditional US market hours. Learn more about how to connect to: sales@blueoceanats. For additional information, please visit our website: www.blueocean-tech.io and follow us on LinkedIn and Twitter.
About FlexTrade Systems Sell-Side Trading Solutions:
FlexTrade Systems is a global financial technology firm that aims to boost trading efficiency by simplifying the complexities of today’s trading workflows through the provision of a unified multi-asset sell-side trading platform. Recognizing its mission-critical role, FlexTrade achieves this goal with unparalleled service and support for high touch and low touch businesses across cash, program trading, futures & options, ETF, swaps, and foreign exchange workflows. Whether the focus is on a market-making, agency, retail, or, proprietary trading desk, FlexTrade can enhance a broker-dealers complete order management lifecycle from order receipt, and trading, to middle and back-office workflows, in a single, technology platform.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005376/en/
Contact information
Blue Ocean Technologies
press@blueocean-tech.io
FlexTrade Systems
Matthew Halicki
Vice President, Marketing
matthew.halicki@flextrade.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gurobi Appoints Dr. Pascal Van Hentenryck to Lead AI Innovation Lab17.2.2026 16:00:00 EET | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, is pleased to announce that Dr. Pascal Van Hentenryck has joined the company as head of the Gurobi AI Innovation Lab (GAIL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217170385/en/ Dr. Pascal Van Hentenryck, Head of AI Innovation Lab, Gurobi Optimization As part of Gurobi’s long-term product and technology strategy, the Gurobi AI Innovation Lab is a focused Research & Development initiative dedicated to advancing the combination of multiple AI technologies with optimization to solve complex, large-scale, and time-critical decision problems. “Pascal brings exceptional leadership across mathematical optimization and complementary AI technologies,” said Dr. Oliver Bastert, CTO, Gurobi Optimization. “While mathematical optimization remains the best approach for most decision problems—as demonstrated by thousands of successful customer implementatio
Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample17.2.2026 15:00:00 EET | Press release
Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, for certain foundational CRISPR-Cas9 intellectual property for use in NGS library preparation. While CRISPR-Cas9 technologies are most commonly associated with their unique ability to find and cut for genome editing, Watchmaker is leveraging it in a fundamentally different way: as a programmable, stoichiometric binding tool to address one of the most persistent and under-optimized steps in NGS workflows – library normalization. “Normalization has quietly become a bottleneck as sequencing throughput has scaled,” said Brian Kudlow, CSO and Founderat Watchmaker Genomics. “This license gives us the freedom to rethink normalization from first principles, using CRISPR-Cas9 in a way that’s orthogonal to editing but highly aligned with modern sequenc
Esri and Pix4D Launch Real-Time Terrestrial Mapping Workflow17.2.2026 15:00:00 EET | Press release
Esri, the global leader in geographic information system (GIS) technology, has launched a terrestrial mapping workflow with Pix4D. A Switzerland-based photogrammetry software company, Pix4D specializes in mobile reality capture and site-digitization. The combined workflow allows field teams to capture and process asset data and manage it within ArcGIS, Esri’s geospatial platform. Field teams use the PIX4Dcatch app with real-time kinematics (RTK) devices to scan trenches and infrastructure. The generated high precision georeferenced records can now be published into Esri’s ArcGIS Online. Scans become 3D models and point clouds, viewable as a Scene Layer. Existing data can also be visualized in augmented reality for instant “as-designed” versus “as-built” verification before closing trenches. “We are focused on turning hidden infrastructure into functional data,” said Andrey Kleymenov, CEO of Pix4D. “By connecting PIX4Dcatch with a compatible RTK device to the Esri ecosystem, we are enab
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression17.2.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint in the ongoing Phase 3 COMP006 trial, the second of two Phase 3 trials, which is evaluating two fixed doses of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The primary endpoint was the difference in change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) scores between the 25 mg and 1 mg groups at Week 6. Two fixed doses – administered 3 weeks apart – of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant reduction in symptom severity with a p-value of <0.001 and a clinically meaningful difference of -3.8 points in change at the primary endpoint. Across COMP005 and COMP006 to date, COMP360 is demonstrating a generally well-tolerated and safe profile, with treatment-emergent adverse events (
BeOne Medicines to Present at Upcoming Investor Conferences17.2.2026 13:00:00 EET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at four upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 am ET; Leerink Global Healthcare Conference on Monday, March 9, 2026 at 11:20 am ET; Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 9:35 am ET; and Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 pm ET Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom